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Ubiquinone (coenzyme Q10 or CoQ10) is a lipid-soluble component of virtually all cell membranes, where it functions
as a mobile electron and proton carrier. CoQ10 deﬁciency is inherited as an autosomal recessive trait and has been
associated with three main clinical phenotypes: a predominantly myopathic form with central nervous system
involvement, an infantile encephalomyopathy with renal dysfunction, and an ataxic form with cerebellar atrophy.
In two siblings of consanguineous parents with the infantile form of CoQ10 deﬁciency, we identiﬁed a homozygous
missense mutation in the COQ2 gene, which encodes para-hydroxybenzoate-polyprenyl transferase. The ArG
transition at nucleotide 890 changes a highly conserved tyrosine to cysteine at amino acid 297 within a predicted
transmembrane domain. Radioisotope assays conﬁrmed a severe defect of CoQ10 biosynthesis in the ﬁbroblasts of
one patient. This mutation in COQ2 is the ﬁrst molecular cause of primary CoQ10 deﬁciency.
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In the mitochondrial respiratory chain, coenzyme Q10
(CoQ10) (MIM 607426) is vital for the transport of elec-
trons from complex I (NADH-ubiquinone oxidoreduc-
tase) and complex II (succinate-ubiquinone oxidoreduc-
tase) to complex III (ubiquinol-cytochrome c reductase)
(Turunen et al. 2004). It is also an antioxidant (Kagan
et al. 1990) and a membrane stabilizer (Turunen et al.
2004), and its oxidized form serves as a cofactor for
uncoupling proteins in brown adipose tissue (Echtay et
al. 2000). Increased levels of CoQ10 may protect cells
from chemotherapy-induced oxidative stress (Brea-Cal-
vo et al., in press).
Deﬁciency of CoQ10 has been associated with three
major clinical phenotypes. A predominantly myopathic
form is characterized by recurrent myoglobinuria and
CNS involvement with seizures, ataxia, or mental re-
tardation (Ogasahara et al. 1989; Sobreira et al. 1997;
Boitier et al. 1998; Lalani et al. 2005). A second variant,
described in three families, manifests as an infantile en-
cephalomyopathy with renal involvement (Ro¨tig et al.
2000; Rahman et al. 2001; Salviati et al. 2005). The
third variant is dominated clinically by ataxia and cer-
ebellar atrophy, with varying involvement of other re-
gions of the CNS, peripheral nerve, and muscle (Mu-
sumeci et al. 2001; Lamperti et al. 2003). In three
siblings with cerebellar ataxia and CoQ10 deﬁciency, we
identiﬁed a homozygous stop codon mutation in the
APTX gene (Quinzii et al. 2005), which is known to
cause ataxia and oculomotor apraxia 1 (AOA1) (Date
et al. 2001; Moreira et al. 2001). This ﬁnding supports
the hypothesis that the ataxic form is a genetically het-
erogeneous entity in which deﬁciency of CoQ10 can be
secondary. Patients with all three forms of CoQ10 deﬁ-
ciency have shown clinical improvements after initiating
oral CoQ10 supplementation. Thus, early diagnosis is of
critical importance in the management of these patients.
The molecular bases for the CoQ10 deﬁciency in most
of these patients remain to be identiﬁed and presumably
involve defects of CoQ10 biosynthesis (ﬁg. 1).
We reported a 33-mo-old boy with infantile enceph-
alomyopathy, nephropathy, and deﬁciency of CoQ10
(Salviati et al. 2005). The disease appeared to be an
autosomal recessive trait because the patient’s parents
were ﬁrst cousins and his 9-mo-old sister with nephro-
pathy also had CoQ10 deﬁciency in ﬁbroblasts. The pro-
band presented with proteinuria at age 12 mo; a renal
biopsy revealed focal and segmental glomerulosclerosis.
Neurological evaluation showed hypotonia, mild psy-
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Figure 1 CoQ10 biosynthetic pathway with eight known bio-
synthetic enzymes denoted as COQ1–COQ8. COQ2, decaprenyl-4-
hydroxybenzoate transferase, mediates the conjugation of the ben-
zoquinone ring with the decaprenyl side chain.
Figure 2 Evolutionary conservation of COQ2. Human amino
acid 297 is normally tyrosine (Y). The ArG transition at nucleotide
890 changes amino acid 297 to cysteine.
chomotor delay, and optic atrophy. His renal function
worsened. At age 18 mo, he developed frequent vom-
iting, and peritoneal dialysis was initiated. He developed
psychomotor regression (loss of the ability to walk or
stand unassisted), tremor, and new-onset status epilep-
ticus with focal electroencephalogram abnormalitiespre-
dominantly in the left occipital region. Brain magnetic
resonance imaging showed cerebellar atrophy, mild dif-
fuse cerebral atrophy, and stroke-like lesions in the left
cingulate cortex and subcortical area. Blood and cere-
brospinal ﬂuid lactate levels were normal. At age 22
months, he developed right hemiplegia, myoclonus, and
swallowing difﬁculties. A muscle biopsy revealed myoﬁ-
bers with excessive succinate dehydrogenase staining but
no ragged-red ﬁbers or cytochrome c oxidase–deﬁcient
ﬁbers. Measurement of respiratory chain enzymes in
muscle extracts showed decreased activities of com-
plexes I III (0.38 mmol/min/g fresh tissue; controlmean
 SD p 1.02  0.38) and II  III (0.22 mmol/min/g;
control mean  SD p 0.70  0.23), whereas other
complexes had normal activities. CoQ10 concentration
in skeletal muscle of the proband was 12 mg/g fresh tissue
(mean  SD of 185 controls p 32.1  6.7). In ﬁbro-
blasts, CoQ10 levels were more severely reduced in both
patients (proband p 19 ng/mg protein; sisterp 18 ng/
mg; mean SD of 15 controlsp 105 14). Activities
of complexes II and III in the ﬁbroblasts of both patients
were decreased (23% and 22%, respectively, of con-
trols), but the defect was corrected after the addition of
50 mM decylubiquinone. After the initiation of CoQ10
supplementation, the neurological manifestations of the
boy improved dramatically.
We performed homozygosity mapping, using ﬂuores-
cently labeled microsatellite markers (ABI Prism Linkage
Mapping Set MD-10 [Applied Biosystems]) of chro-
mosomal loci for the eight known human genes (COQ1–
COQ8) encoding CoQ10 biosynthetic proteins. Three
chromosomal loci revealed homozygosity in the affected
individuals: chromosomes 14q24 (COQ6), 12q24
(COQ5), and 4q21 (COQ2). Primer sequences and PCR
conditions for ampliﬁcation of candidate genes are avail-
able from the author on request. Sequencing of the three
candidate genes in the patients revealed only one non-
synonymous change: in COQ2, encoding para-hydrox-
ybenzoate (PHB)–polyprenyl transferase (EC 2.5.1.39),
we found a homozygous ArG transition at nucleotide
890, which is predicted to change amino acid 297 from
tyrosine to cysteine in the third of six predicted trans-
membrane domains of the COQ2 protein (Forsgren et
al. 2004) (ﬁg. 2). The transition was heterozygous in
both parents and absent in DNA from 100 healthy in-
dividuals tested by RFLP analysis using AﬂII restriction
endonuclease digestion of PCR-ampliﬁed DNA frag-
ments. We also sequenced COQ1, to exclude a defect
in transprenyl transferase. We did not identify any mu-
tations in COQ2 by sequencing genomic DNA in seven
additional patients with CoQ10 deﬁciency in skeletal
muscle (three with the predominantly myopathic form,
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Table 1
Biochemical Assays to Measure COQ2 Activity
Fibroblasts CoQ10 Synthesis
a
Percent of
Control Mean
Assay 1b:
Patient 1 388 DPM/mg protein/h 22
Control 1,733  747 DPM/mg protein/h 100
Assay 2c:
Patient 1 48 pmol/mg protein/h 36
Control 130  18 pmol/mg protein/h 100
a In both assays, radiolabeled CoQ10 was isolated by HPLC and
was quantitated in a scintillation counter. Controls are measured
as means  SDs ( ). DPM p decays per minute.np 5
b Cultured cells were incubated for 24 h with 0.1 mCi 14C-PHB
(50 Ci/mol speciﬁc activity).
c Fibroblast homogenates were incubated with 3H-radiolabeled
decaprenyl-PP.
two with severe ataxia, and two with infantile-onset
encephalomyopathy).
To conﬁrm that the patients had a defect of CoQ10
biosynthesis, we performed biochemical assays to mea-
sure incorporation of each of two radiolabeled sub-
strates (ﬁg. 1). For the ﬁrst assay, ﬁbroblasts from the
proband and a control were plated in six separate wells
of 24#6.5–mm plates (40,000 cells/well) and were
cultured using Dulbecco’s modiﬁed Eagle medium
(DMEM) with 20% fetal calf serum (Nishigaki et al.
2003). After four days, the medium was replaced by
fresh DMEM with 20% fetal calf serum and 0.1 mCi of
14C-PHB (50 Ci/mol speciﬁc activity). After incubation
for an additional 24 h, cells were washed twice with PBS
and were detached from the bottom of the wells with
the use of 0.5 ml of 1% SDS, followed by shaking for
10 min at room temperature (repeated once). The con-
tents of each plate were combined (3 ml total), and 0.2
ml was saved for protein determination (Lowry et al.
1951). The remaining pooled suspensionswere subjected
to hexane extraction. CoQ10 was extracted after the ad-
dition of 4 ml hexane-ethanol (5/2 v/v) and was vortexed
for 2 min. After centrifugation at 2,500 rpm at room
temperature for 5 min, the upper phase was carefully
transferred into a 20-ml glass scintillation vial (per-
formed twice for each sample). The combined extract
was evaporated under a gentle stream of N2 gas, and
the residue was dissolved in 0.15 ml of 1-propanol. An
aliquot of 50 ml of the extract was directly injected into
a high-performance liquid chromotography (HPLC) sys-
tem with a C18 reversed-phase column and an electro-
chemical detector. The waste line of HPLC was con-
nected to a fraction collector, which was programmed
to collect 1.0 ml of fractions per minute. CoQ10 peak
was identiﬁed by speciﬁc retention time determined after
injection of a known amount of authentic CoQ10. The
amount of radioactivity in the collected fraction was
determined in a Packard scintillation counter.
In the second COQ2 assay, enzymatic activity in ﬁ-
broblast lysate was measured by a described method
(Kalen et al. 1990), with modiﬁcations. The incubation
mixture contained 250 nCi of 3H-radiolabeled deca-
prenyl pyrophosphate (decaprenyl-PP) (20 Ci/mmol) sol-
ubilized in 25 mL of 1%Triton X-100, 50mMpotassium
phosphate at pH 7.5, 10 mM MgCl2, 5 mM ATP, 20
mM 4-hydroxybenzoic acid, and ﬁbroblast lysate (∼1 mg
protein) in a total volume of 0.5 ml. After incubation
at 37C in a shaking water bath for 60 min, the reaction
was stopped by the addition of 1 ml ethanol followed
by 1ml of 0.1-M SDS. Hexane extractionwas performed
as described above, and the residue was dissolved in 0.15
ml of 1-propanol. An aliquot of 50 ml was injected onto
the HPLC. Fraction collection and radioactivity mea-
surement were performed as described above.
In the ﬁrst assay, after incubating ﬁbroblasts from a
control and patient 1 with 14C-PHB, the level of radio-
labeled CoQ10 in the patient’s ﬁbroblasts was ∼22% of
the control mean (patient p 338 decays per min/mg
protein/h; control mean  SD p 1,733  747, np
) (table 1). In the second assay, homogenates from pa-5
tient 1 and control ﬁbroblasts incubated with 3H-radio-
labeled decaprenyl-PP revealed that COQ2 activity in
the patient was only 36% relative to the control mean
(patient p 48 pmol/mg protein/h; control mean  SD
p 130  18, ) (table 1). Unfortunately, the ﬁ-np 5
broblasts of the proband’s sister did not replicate suf-
ﬁciently to allow measurement of CoQ10 biosynthesis in
her cells.
Cells synthesize CoQ10 de novo, starting with synthe-
sis of the PHB ring and the polyisoprenyl tail, which
anchors CoQ10 to membranes. The length of this tail
varies among different organisms. In humans, the side
chain is comprised of 10 isoprenyls producing CoQ10,
whereas rats predominantly generate CoQ9. In yeast,
mutations in any of the eight COQ genes block CoQ10
synthesis, and CoQ10-deﬁcient cells cannot grow on non-
fermentable carbon sources because of respiratory chain
dysfunction, despite the accumulation of the interme-
diate demethoxy-CoQ10 (Gin et al. 2003). These yeast
strains are also more sensitive to oxidative stress. These
results indicate that CoQ10 cannot be replaced by an-
other molecule in the cell and suggest that human dis-
eases due to primary CoQ10 deﬁciency may present as
severe mitochondrial encephalomyopathies.
Although deﬁciency of CoQ10 in skeletal muscle was
originally described in 1989 and has been reported in
at least 35 patients, the pathogenic mechanisms had been
undeﬁned (Ogasahara et al. 1989; Sobreira et al. 1997;
Boitier et al. 1998; Ro¨tig et al. 2000; Di Giovanni et al.
2001; Musumeci et al. 2001; Rahman et al. 2001; Van
Maldergem et al. 2002; Lamperti et al. 2003; Aure et
al. 2004; Gironi et al. 2004; Lalani et al. 2005). The
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wide variety of clinical presentations associated with
CoQ10 deﬁciency has suggested genetic heterogeneity,
probably related to the many steps involved in the CoQ10
biosynthesis.
We have identiﬁed the ﬁrst molecular cause of primary
CoQ10 deﬁciency, a mutation in the gene encoding PHB-
polyprenyl transferase (COQ2), the second enzyme in
the biosynthetic pathway of CoQ10 (ﬁg. 1). PHB-poly-
prenyl transferase mediates the conjugation of the ben-
zoquinone ring with the decaprenyl side chain and, thus,
plays a central role in the biosynthesis of CoQ10 (Fors-
gren et al. 2004).
The GrA mutation at nucleotide 890 of COQ2 ap-
pears to exert a pathogenic effect by blocking ubiqui-
none synthesis. Evidence supporting pathogenicity in-
cludes: (1) the substitution of a well-conserved aromatic
tyrosine amino acid by a polar uncharged cysteine in a
predicted transmembrane domain of the protein, (2) ab-
sence of the mutation in 100 unrelated controls (200
alleles), and (3) the signiﬁcantly decreased rate of CoQ10
synthesis, indicated by the reduced incorporation of ra-
diolabeled PHB and decaprenyl-PP into CoQ10 in skin
ﬁbroblasts of the proband (23%–25% of control
ﬁbroblasts).
The pathogenic effects of CoQ10 deﬁciency in humans
are uncertain. Lack of CoQ10 in mitochondria will dis-
rupt the ﬂow of reducing equivalents to respiratory chain
complex III from complexes I and II, which, in turn, will
lead to decreased ATP synthesis by oxidative phos-
phorylation. Respiratory chain defects typically cause
encephalomyopathies due to the high energy require-
ments of these organs (DiMauro and Schon 2003); it is,
therefore, not surprising that CoQ10 deﬁciency should
also affect brain and muscle. In addition, because CoQ10
functions as an antioxidant, CoQ10 deﬁciency may pref-
erentially affect postmitotic cells, such as neurons and
muscle, which are particularly vulnerable to oxidative
damage because they cannot replace dysfunctional cells.
Furthermore, to function as an antioxidant, CoQ10 must
be in the reduced form, but only 20% of the molecule
is reduced in the brain (Naini et al. 2003). Brain vul-
nerability to oxidative stress has been demonstrated in
neurodegenerative diseases, such as Friedreich ataxia
(Puccio and Koenig 2002) and ataxia associated with
deﬁciency of vitamin E (Yokota et al. 2001), which, like
CoQ10, is a lipid-soluble antioxidant in biological mem-
branes. Finally, in Schizosaccharomyces pombe with de-
fective PHB-polyprenyltransferase, there is also in-
creased vulnerability to oxidative stress, which is dem-
onstrated both by increased sensitivity to pro-oxidants
like H2O2 and Cu
2 and by the ability of supplemental
antioxidants (cysteine, glutathione, and a-tocopherol) to
restore growth in glucose medium (Uchida et al. 2000).
Renal failure has been described in the infantile var-
iant of CoQ10 deﬁciency and was present in our patients
(Ro¨tig et al. 2000). The vulnerability of the kidney is
more difﬁcult to explain, but lipid peroxidation and al-
tered mitochondrial function have been implicated in
congenital nephrotic syndrome and glomerular protein-
uria (Neale et al. 1994; Holthofer et al. 1999).
This is the ﬁrst report of a molecular defect causing
primary human CoQ10 deﬁciency and the initial descrip-
tion of defects in human PHB-polyprenyl transferase.
Further studies are needed to understand the pathogen-
esis of this disease, and the detection of mutations in
COQ2 in other patients will better deﬁne possible phe-
notypic variants in this condition. The availability of
genetic testing will allow the initiation of early thera-
peutic intervention, even presymptomatically, in this oth-
erwise life-threatening infantile encephalomyopathy re-
sponsive to CoQ10 supplementation.
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